NEUROD1-dominant SCLC has been shown to respond to aurora kinase inhibitors [11], while preclinical studies have suggested that POU2F3-dominant tumors may be sensitive to IGF-1R inhibitors, PARP inhibitors, and lurbinectedin [8,12]. Here, IGF1R is linked to small cell lung carcinoma.